Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma

Chimeric antigen receptor T (CAR-T) cell therapy is an attractive strategy for patients with relapsed or refractory hematological malignancies including multiple myeloma (MM). T cells are engineered to attack malignant cells that express tumor-associated antigens and better efficacy could be achieve...

Full description

Bibliographic Details
Main Authors: Mengyi Du, Linlin Huang, Haiming Kou, Chenggong Li, Yu Hu, Heng Mei
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
thrombocytopenia
ITP
CAR-T therapy
multiple myeloma
MAIPA
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.898341/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.898341/full

Similar Items